| Simon Neil Pimstone |
Simon Neil Pimstone is the founder of Xenon Pharmaceuticals, Inc., which was founded in 1996. He currently holds the position of Non-Executive Chairman at Xenon Pharmaceuticals, Inc. Dr. Pimstone is also currently the Chairman at Eupraxia Pharmaceuticals, Inc., Topirx Pharmaceuticals, Inc., Alpha-9 Oncology, Inc., and XYON Health, Inc. He is a Director at XYON Health, Inc. Dr. Pimstone is a Member of Young Presidents' Organization (Canada). In his former positions, he was the Chairman of LifeSciences British Columbia, Vice Chairman of BIOTECanada, and Vice Chairman of British Columbia Clinical Research Infrastructure Network. He also served as the Chairman of Providence Health Care Research Institute, Accuro Technologies, Inc., and the Michael Smith Foundation for Health Research. Dr. Pimstone was a Director at Enject, Inc., Allergen NCE, Inc., Indel Therapeutics, Inc., Centre for Molecular Medicine & Therapeutic, Cyon Therapeutics, Inc., and Providence Health Care (Vancouver). He held the position of Clinical Associate Professor at the University of British Columbia. Dr. Pimstone is a Member of the Science, Technology & Innovation Council. He completed his undergraduate degree at the University of Cape Town in 1991 and obtained his doctorate degree from the University of Amsterdam in 1998. |
| Christopher Kenney |
Christopher Kenney is currently the Chief Medical Officer at Xenon Pharmaceuticals, Inc. He previously worked as the Senior Vice President-Medical Affairs at Acorda Therapeutics, Inc. from 2016 to 2019, as the Chief Medical Officer at Cadent Therapeutics, Inc. from 2019 to 2020, and as the Senior Vice President-Clinical Development at Biotie Therapies, Inc. from 2013 to 2016. |
| Sheila M. Grant |
Sheila M. Grant is currently the Executive VP-Research & Development Operations at Xenon Pharmaceuticals, Inc. Prior to her current position, she served as the Chief Operating Officer at Correvio Pharma Corp. from 2013 to 2020. Additionally, she worked as a Consultant at Twinstrand Therapeutics, Inc. Ms. Grant holds an MBA from Simon Fraser University, a graduate degree from the London School of Hygiene & Tropical Medicine, and an undergraduate degree from the University of Essex. |
| Andrea DiFabio |
Andrea DiFabio is currently the Chief Legal Officer & Secretary at Xenon Pharmaceuticals, Inc. She previously worked as the Chief Research & Business Development Counsel at Biogen, Inc. from 2006 to 2017, Vice President & Deputy General Counsel at PAREXEL International Corp., Chief Legal Officer at Codiak BioSciences, Inc., and Secretary, Chief Legal Officer & Executive VP at Bioverativ, Inc. from 2016 to 2018. She also served as the Director-Northeast Chapter at the Association of Corporate Counsel. Ms. DiFabio received her undergraduate degree from Boston University and her graduate degree from Northeastern University. |
| Chris von Seggern |
Chris von Seggern is currently the Chief Commercial Officer at Xenon Pharmaceuticals, Inc. He previously worked as a Partner at Clearview Healthcare Partners LLC from 2011 to 2019. Dr. von Seggern holds an MBA from Northeastern University, an undergraduate degree from The Pennsylvania State University, and graduate and doctorate degrees from The Johns Hopkins University School of Medicine. |
| Sherry Aulin |
Sherry Aulin is currently the Chief Financial Officer at Xenon Pharmaceuticals, Inc. She previously worked as a Senior Manager at KPMG LLP (Canada) from 2004 to 2011. Ms. Aulin completed her undergraduate degree at the University of British Columbia. |
| Ian C. Mortimer |
Ian C. Mortimer is currently the President, Chief Executive Officer & Director at Xenon Pharmaceuticals, Inc. He is also the President, Treasurer & Director at Xenon Pharmaceuticals USA, Inc. Additionally, he serves as the Director at Perimeter Medical Imaging AI, Inc. Mr. Mortimer previously worked as an Independent Director at Appili Therapeutics, Inc. and as a Director at Perimeter Medical Imaging, Inc. Prior to that, he was the Chief Financial Officer & Executive Vice President at Arbutus Biopharma Corp. Mr. Mortimer holds an MBA from Queen's University and an undergraduate degree from the University of British Columbia. |
| Mohammad Magdy Mohamed Azab |
Mohammad Magdy Mohamed Azab currently works at Pyramisa Hotels, as Vice Chairman & MD-Financial Affairs, DURECT Corp., as Independent Director, Xenon Pharmaceuticals, Inc., as Independent Director from 2003, Lisata Therapeutics, Inc., as Independent Director from 2022, American Society of Clinical Oncology, Inc., as Member, American Society of Hematology, as Member, European Society for Medical Oncology, as Member, and International Association for the Study of Lung Cancer, as Member. Dr. Azab also formerly worked at Intradigm Corp., as President, Chief Executive Officer & Director from 2006 to 2010, Astex Pharmaceuticals, Inc., as Chairman from 2020 to 2022, Sernova Corp., as Independent Director from 2021 to 2023, Chemokine Therapeutics Corp., as Director from 2006 to 2007, QLT, Inc., as Chief Medical Officer, EVP-Research & Development from 1997 to 2005, SuperGen, Inc., as Chief Medical Officer from 2009 to 2011, Astex Therapeutics Ltd., as Chief Medical Officer, American Association for Cancer Research, as Member, and Sanofi-Synthelabo, Inc., as Manager-International Medical Oncology from 1989 to 1992. Dr. Azab received his doctorate degree in 1979 from the University of Cairo, graduate degree from Université de Paris XI Paris Sud, graduate degree from Université Pierre et Marie Curie, and Masters Business Admin degree in 2001 from Richard Ivey School of Business. |
| Elizabeth A Garofalo |
Elizabeth A Garofalo currently works at ACADIA Pharmaceuticals, Inc., as Independent Director from 2020, Xenon Pharmaceuticals, Inc., as Independent Director from 2021, Alector, Inc., as Independent Director from 2021, Institute For Advanced Clinical Trials For Children, as Director, and EAG Pharma Consulting LLC, as Principal from 2016. Dr. Garofalo also formerly worked at Exicure, Inc., as Chairman from 2022 to 2023, Pfizer Inc., as Head-Neuroscience & Worldwide Regulatory Affairs, Novartis International AG, as Global Head-Clinical Development & Senior VP, and Astellas Pharma Global Development, Inc., as VP & Head-Neuroscience Therapy Area. Dr. Garofalo received her undergraduate degree from Purdue University and doctorate degree from The Indiana University School of Medicine. |
| Gary Patou |
Gary Patou is currently working as an Independent Director at Xenon Pharmaceuticals, Inc., Director & Chief Medical Officer at Biointervene, Inc., Advisor at Scleroderma Research Foundation, and Chief Medical Officer at Star Therapeutics, Inc. He previously worked as President & Chief Executive Officer at Cerimon Pharmaceuticals, Inc., Director at Ligand UK Ltd., Senior VP, Director-Project & Portfolio Management at GSK Plc and Smithkline Beecham Pharmaceuticals Ltd., Chief Medical Officer & Executive Vice President at Oscient Pharmaceuticals Corp., President at Genesoft Pharmaceuticals, Inc., Chief Medical Officer at Peplin Ltd. and Cerimon Pharmaceuticals, Inc., Senior Medical Advisor at Chiasma, Inc., Advisor at MPM BioImpact, Inc., and Chief Medical Officer at Pacira Biosciences, Inc., True North Therapeutics, Inc., and Blade Therapeutics, Inc. He completed his undergraduate, graduate, and doctorate degrees from the University of London. |
| Steven Gannon |
Steven Gannon's current jobs include being a Director at enGene, Inc. since 2017, an Independent Director at Xenon Pharmaceuticals, Inc. since 2015, a Director at Altasciences Co., Inc. since 2021, and an Independent Director at Fusion Pharmaceuticals, Inc. since 2020. His former jobs include being a Director at 2941881 Canada, Inc., a Director-Finance & Administration at AstraZeneca Canada, Inc. from 1996 to 1999, a Director at Aerogen Ltd. from 2018 to 2020, an Independent Non-Executive Director at Advanced Accelerator Applications SA from 2014 to 2018, and the Chief Financial Officer at CryoCath Technologies, Inc. from 1999 to 2006. He also served as the Chief Financial Officer, Treasurer & Senior VP at Aptalis Pharma LLC from 2006 to 2014, and as the Chief Financial Officer at Mallinckrodt Medical, Inc. from 1989 to 1995. Additionally, he held the position of Chief Financial Officer, Treasurer & Senior VP at Aptalis Holdings, Inc. in 2008. Mr. Gannon obtained his undergraduate degree from Concordia University in 1983. |
| Dawn A. Svoronos |
Dawn A. Svoronos is currently serving as the Chairman at Theratechnologies, Inc., Lead Independent Director at Xenon Pharmaceuticals, Inc., Independent Director at Adverum Biotechnologies, Inc., Director at AgNovos Healthcare LLC, Director at West Island Palliative Care Residence, Director at ACELYRIN, Inc., and Director at Teresa Dellar Palliative Care Residence. Previously, she held positions such as Chairman at The Centre for Drug Research & Development, Independent Director at PTC Therapeutics, Inc., Director at IGM Financial, Inc., Director at Endocyte, Inc., Independent Director at Medivation LLC (California), Director at AERIC, Inc., Independent Director at Global Blood Therapeutics, Inc., President at Merck Canada, Inc., President-Europe & Canada Region at Merck & Co., Inc., and Principal at Analgesics Solutions LLC and Osteoporosis Canada. She obtained her undergraduate degree from Carleton University. |
| Clarence Patrick Machado |
Clarence Patrick Machado is the founder of Medivation, Inc. (founded in 1995) and Medivation LLC (California) (founded in 1995). He held the title of Director at both companies from 2014 to 2016. Mr. Machado's current job(s) include Chairman at Adverum Biotechnologies, Inc. (since 2017), Independent Director at Chimerix, Inc. (since 2014), Independent Director at Xenon Pharmaceuticals, Inc. (since 2020), Director at Turnstone Biologics, Inc., Independent Director at Arcus Biosciences, Inc. (since 2019), Director at Auransa, Inc., Director at Roivant Sciences, Inc., Director at ACELYRIN, Inc. (since 2021), and Member-Supervisory Board at Therachon Holding GmbH. Mr. Machado's former job(s) include Chairman at Armaron Bio Ltd., Independent Director at Inotek Pharmaceuticals Corp. (from 2016 to 2018), Director at Principia Biopharma, Inc. (from 2019 to 2020), Independent Director at Turning Point Therapeutics, Inc. (from 2019 to 2022), Independent Director at Roivant Sciences Ltd. (from 2016 to 2022), Independent Director at SCYNEXIS, Inc. (from 2015 to 2019), Independent Director at Endocyte, Inc. (in 2018), Chief Financial Officer, Director & Senior VP at Medivation Neurology LLC (from 2003 to 2004), Director at Sio Gene Therapies, Inc. (from 2017 to 2018), Director at Axovant Sciences, Inc. (from 2017 to 2018), Independent Director at Montes Archimedes Acquisition Corp., Independent Director at Turnstone Biologics Corp. (from 2018 to 2024), Chief Legal Counsel at Chiron Corp., Chief Financial Officer at Orion Acquisition Corp. II, Consultant at Cytyc Corp. (in 2002), Principal at Morrison & Foerster LLP, and Chief Financial Officer & Senior Vice President at Pro-Duct Health, Inc. (from 1998 to 2001). Mr. Machado's education includes an undergraduate degree from Santa Clara University (conferred in 1986) and a graduate degree from Harvard Law School (conferred in 1989). |
